Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aquinox Pharmaceuticals has started a double-blinded, placebo-controlled, single ascending dose, multiple ascending dose and food effects Phase 1 study evaluating AQX-1125.
Subscribe to our email newsletter
Aquinox Pharma’s Phase 1 AQX-1125 is a three part study in healthy volunteers.
The primary objectives of Phase I are to evaluate the safety, tolerability and pharmacokinetics of AQX-1125 administered orally once-daily.
Additionally, the secondary objective includes investigating the pharmacodynamics of AQX-1125 through the utilization of biomarkers.
Aquinox Pharma chairman, president and CEO David Main said that AQX-1125 has demonstrated efficacy in preclinical models of inflammatory disease and has desirable pharmaceutical properties making it a strong development candidate.
Aquinox chief medical officer David Chernoff said that the Phase I study will enroll 52 normal health volunteers at a single center in Europe.
"We believe this study will provide us with the data necessary to progress our clinical programs forward into multiple proof-of-concept studies in different indications," Chernoff said.